Drugs moving into the clinic: 38

By Staff Reporter

- Last updated on GMT

The latest in a series of periodic roundups of drugs that have
moved from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
industry regulators.
Sponsor Name Indication Mechanism
BioMarin PEG-PAL (formerly Phenylase) Metabolism - phenylketonuria (PKU) PEGylated recombinant phenylalanine ammonia lyase to reduce levels of plasma phenylalanine. IND filed
Biocompatibles International CellBeads CNS - stroke Stem cell product given to patients immediately after haemorrhagic stroke
LifeCycle Pharma LCP-Siro (sirolimus/ rapamycin) Immune - prevention of organ rejection Sirolimus or rapamycin is an imunosuppressant (marketed by Wyeth as Rapamune). It binds to FK-binding protein 12 (FKBP12) and then to mammalian target of rapamycin (mTOR) complex 1. This limits the response to interleukin-2 (IL-2) and therefore blocks activation of T and B cells. Product is new formulation to try and achieve increased bioavailability and reduced dosing.
Rigel / Pfizer R343 Allergic asthmaIgE receptor inhibition in respiratory tract mast cells by blocking activation of syk kinase

Related topics: Preclinical Research

Related news

Show more